TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1710802
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug for 6 months
Study: 1710802
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug for 18 months
Study: 1710802
Drug: Post-treatment clinical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment clinical course
Study: 6274563
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg/kg) after 8 weeks
Study: 21980168
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg MDMA
Study: 21980168
Drug: 1.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg/kg MDMA
Study: 21983032
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg MDMA and 1.6 mg/kg MDMA
Study: 11573514
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser irradiation (G 1, 2 Hz and 136‐184 mJ/pulse)
Study: 11573514
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser irradiation (G 2, 2 Hz and 170‐230 mJ/pulse)
Study: 11573514
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy laser irradiation (G 2)
Study: 1539791
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution 0.25%
Study: 31356475
Drug: 4% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% albumin in lactated Ringer's solution
Study: 31356475
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution alone
Study: 24986373
Drug: Non-matched saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-matched saline infusion (sham-controlled group)
Study: 20516538
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone acetate (1.5 ml) and hyaluronidase (1500 IU) at weekly interval for 22 weeks
Study: 20516538
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (10 mg/ml) and hyaluronidase (1500 IU) at 15 days interval for 22 weeks
Study: 14685950
Drug: Insight: A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight: A cognitive enhancement program for women (short-term cognitive group therapy)
Study: 10232737
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell add-back therapy (up to 3 doses based on risk factors for GVHD)
Study: 22502623
Drug: CAM intervention
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM intervention (acupuncture, neural therapy with 1% procaine injection, cupping and bleeding, TCM herbs)
Study: 22502623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (wait-list, delayed treatment)
Study: 18720710
Drug: Trimetazidin (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidin (TMZ) 35 mg
Study: 15802415
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg-10 mg-5 mg-5 mg intravenously every 12 hours)
Study: 11787475
Drug: Moxonidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.4 mg)
Study: 1989736
Drug: Epidural butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural butorphanol 1 mg
Study: 1989736
Drug: Epidural butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural butorphanol 4 mg
Study: 24733807
Drug: Piperacillin/tazobactam with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam with tigecycline (4.5 g IV every 8 hours + 50 mg IV every 12 hours; loading dose 100 mg)
Study: 24733807
Drug: Piperacillin/tazobactam monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam monotherapy
Study: 22036036
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 3000 mg in divided doses
Study: 22036036
Drug: Ketamine (0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.23 mg/kg bolus, followed by 0.58 mg/kg for 30 min, then 0.29 mg/kg for 40 min)
Study: 19769634
Drug: Oral Sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Sodium Phosphosoda (OSPS)
Study: 19769634
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PEG and OSPS (PEG+OSPS)
Study: 16321186
Drug: Alfacalcidol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 1.0 microg/d plus calcium carbonate 750 mg Tid
Study: 16321186
Drug: Alfacalcidol 0.5
Normalized name: alfacalcidol 0.5 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 0.5 microg/d plus calcium carbonate 750 mg Tid
Study: 16321186
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 750 mg Tid
Study: 11895272
Drug: Healthy School
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy School and Drugs project (intervention)
Study: 7615230
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg orally once daily for 7 days (n=8)
Study: 2613380
Drug: Metoprolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50-100 mg twice a day)
Study: 2613380
Drug: Verapamil (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (40-80 mg three times a day)
Study: 2613380
Drug: Digoxin (0.25-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25-0.5 mg daily)
Study: 28077460
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glyburide and metformin
Study: 28077460
Drug: Glyburide and
Normalized name: Glyburide and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide and Metformin
Study: 25541376
Drug: Implantable pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable pulmonary artery pressure monitoring device (treatment group)
Study: 25541376
Drug: Implantable pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable pulmonary artery pressure monitoring device (treatment group) in COPD subgroup
Study: 19050164
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily for 28 days
Study: 11343480
Drug: Medical antireflux
Normalized name: VALVE,ANTIREFLUX UROCARE #6001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical antireflux therapy
Study: 11343480
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (fundoplication)
Study: 9702845
Drug: Eptastigmine 8
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine 8 mg
Study: 7608318
Drug: Eptastigmine 20
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine 20 mg
Study: 9702845
Drug: Eptastigmine 32
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine 32 mg
Study: 9702845
Drug: Eptastigmine 40
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine 40 mg
Study: 2685654
Drug: Sinemet CR
Normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sinemet CR 50/200 mg
Study: 2685654
Drug: Conventional carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional carbidopa/levodopa 25/250 mg
Study: 790125
Drug: Raubasine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raubasine (90 mg daily for 1-2 weeks)
Study: 27801990
Drug: Eculizumab (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (administered for 4 weeks alongside standard IVIg treatment)
Study: 25133710
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (1.8 g of protein·kg bw(‐1)·day(‐1))
Study: 25133710
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (0.85 g of protein·kg bw(‐1)·day(‐1))
Study: 19350183
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser treatment, lesions treated twice weekly for 13 weeks, starting with 50 to 100 mJ/cm2 and increasing by 50 mJ/cm2 until erythema appeared, for a maximum of 25 sessions or until 100% repigmentation.
Study: 12004315
Drug: Untreated control
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated control patches
Study: 17032095
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) combined with medication tapering
Study: 17032095
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonspecific therapy)
Study: 14645937
Drug: Behavioural cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioural cessation programme (four session treatment administered individually by a health educator, plus monthly brief phone calls until one year follow up)
Study: 10386471
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg s.c. monthly + Flutamide 250 mg t.i.d. + Placebo daily
Study: 10386471
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg s.c. monthly + Finasteride 10 mg (2 x 5 mg daily) + Placebo t.i.d.
Study: 10386471
Drug: Finasteride 10
Normalized name: finasteride 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 10 mg (2 x 5 mg daily) + Flutamide 250 mg t.i.d.
Study: 8697708
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily activities
Study: 31839082
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 7.5 mg plus fentanyl 20 μg (Group F)
Study: 31839082
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 10 mg (Group B)
Study: 27849380
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg/day plus dapagliflozin 10 mg/day
Study: 27849380
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg/day plus placebo
Study: 27849380
Drug: dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dapagliflozin 10 mg/day plus placebo
Study: 26343594
Drug: Risperidone +
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone + Dextromethorphan (60 mg/day)
Study: 25099079
Drug: Erythropoietin (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (40,000 IU, 8 weekly infusions)
Study: 18278305
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 75 mg/kg
Study: 18278305
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 50 mg/kg plus hydroxyzine 2.0 mg/kg
Study: 12177096
Drug: Low-dose suramin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose suramin (3.192 g/m²)
Study: 12177096
Drug: Intermediate-dose suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose suramin (5.320 g/m²)
Study: 12177096
Drug: High-dose suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose suramin (7.661 g/m²)
Study: 10094358
Drug: Continuous heparin
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous heparin drip
Study: 3174726
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMW heparin) - 15,000 Anti X-activated Factor Units, daily subcutaneous injection for 7 days after operation
Study: 3174726
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin - 5,000 International Units, 2 daily subcutaneous injections for 7 days after operation
Study: 18928413
Drug: Ziprasidone 80
Normalized name: ziprasidone 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 80 or 160 mg/d (fixed dose) during Period 1
Study: 18928413
Drug: Ziprasidone flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone flexible doses (20-160 mg/d) during Period 2
Study: 21775917
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate (RL) solution without colloid
Study: 9868725
Drug: Antianxiety drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianxiety drug (diazepam) with vitamin B complex
Study: 7979299
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of oral diethyldithiocarbamate (DTC) per m2 weekly for 12 weeks
Study: 3187472
Drug: Midazolam (5‐7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5‐7.5 mg i.m., weight related)
Study: 3764397
Drug: Hydrocodonum (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodonum (15 mg i.m.)
Study: 26549958
Drug: Naikan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naikan therapy
Study: 11667990
Drug: Ringer‐Lactate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer‐Lactate solution
Study: 8209072
Drug: Salbutamol via
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol via metered dose inhaler (MDI)
Study: 26303741
Drug: Medicine control
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine control
Study: 21214610
Drug: TZP-101 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZP-101 (80 μg/kg)
Study: 6356177
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg haloperidol tablets (average 4.0 tablets, 20.0 mg/day)
Study: 6356177
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg haloperidol tablets (average 3.9 tablets, 58.0 mg/day)
Study: 6356177
Drug: Higher oral
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher oral haloperidol doses
Study: 28183347
Drug: Prehospital administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehospital administration of thawed plasma
Study: 22024668
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg/day (force-titrated to 10 mg/day after 1 week) in the morning
Study: 22024668
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg/day (force-titrated to 10 mg/day after 1 week) in the evening
Study: 19503772
Drug: Thermal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal laser treatment
Study: 19503772
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of steroids
Study: 19503772
Drug: Pharmaceuticals containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceuticals containing antibodies against vascular endothelial growth factor (VEGF)
Study: 17244293
Drug: Cash and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash and Counseling (treatment group) among elderly in Florida
Study: 11928802
Drug: Breast conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservation therapy as a primary therapeutic procedure
Study: 7726705
Drug: Didanosine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (500 mg/d)
Study: 7726705
Drug: Didanosine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (750 mg/d)
Study: 7726705
Drug: Zidovudine, Didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, Didanosine (500 mg/d), Didanosine (750 mg/d)
Study: 2304988
Drug: Silicone-gel implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone-gel implants
Study: 2304988
Drug: Saline-filled implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline-filled implants
Study: 6798924
Drug: Rosoxacin 100
Normalized name: rosoxacin
DrugBank: Rosoxacin (DB00817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosoxacin 100 mg
Study: 6798924
Drug: Rosoxacin 200
Normalized name: rosoxacin
DrugBank: Rosoxacin (DB00817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosoxacin 200 mg, 300 mg, or 400 mg
Study: 25004196
Drug: Yoga (1-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga (1-hour class weekly for 10 weeks)
Study: 25004196
Drug: Control (supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (supportive women's health education, 1-hour class weekly for 10 weeks)
Study: 21733292
Drug: Drug cues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug cues in abstaining smokers
Study: 20691131
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus PRSF-L477 (1 × 10¹¹ cfu daily for 3 weeks)
Study: 10944134
Drug: Standard-dose neuraxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose neuraxis irradiation (36 Gy in 20 fractions)
Study: 10944134
Drug: Reduced-dose neuraxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose neuraxis irradiation (23.4 Gy in 13 fractions)
Study: 1408298
Drug: Facet joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facet joint injection
Study: 18783503
Drug: Gabapentin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (900 mg/day)
Study: 3874009
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg tid aspirin (ASA) plus 75 mg tid dipyridamole (DP)
Study: 3874009
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg tid aspirin (ASA)
Study: 3874009
Drug: Platelet-inhibiting therapy
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-inhibiting therapy (ASA + DP)
Study: 27902493
Drug: Intravenous amisulpride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amisulpride (5 mg)
Study: 23715188
Drug: Amisped® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisped® (5 mg montelukast chewable tablets)
Study: 23715188
Drug: Singulair® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singulair® (5 mg montelukast chewable tablets)
Study: 20131276
Drug: Golimumab 4
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab 4 mg/kg plus MTX
Study: 17267204
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate plus etoposide and ifosfamide
Study: 17267204
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate plus doxorubicin
Study: 12377864
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% amethocaine gel applied for 30 min prior to the radial arterial puncture
Study: 12377864
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% amethocaine gel
Study: 4067888
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy for 24 weeks starting at 10 weeks post-stroke
Study: 28479412
Drug: Family-focused grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused grief therapy (not specified dosage or duration)
Study: 3472139
Drug: Oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral scopolamine hydrobromide solution (ScHBr), 0.02 mg/kg total body weight, rinsed in the mouth for 5 minutes before swallowing
Study: 3472139
Drug: Oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral scopolamine hydrobromide solution (ScHBr) during clinical dental examination procedures
Study: 3472139
Drug: Oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral scopolamine hydrobromide solution (ScHBr)
Study: 28718320
Drug: Prednisolone 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 37.5 mg
Study: 24002499
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment (nucleotide/nucleoside analogs: Lamivudine, adefovir dipivoxil, or entecavir)
Study: 24002499
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment
Study: 30983087
Drug: Prasugrel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (20 mg loading/3.75 mg maintenance)
Study: 30983087
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading/75 mg maintenance)
Study: 25740805
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% natamycin
Study: 25740805
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% voriconazole
Study: 15262190
Drug: EPA-rich oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-rich oil (9 g oil/day for 4 weeks)
Study: 15262190
Drug: DHA-rich oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich oil (9 g oil/day for 4 weeks)
Study: 15262190
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil, 9 g oil/day for 4 weeks)